Why These 10 Firms Soared on Monday

2. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals jumped by 23.52 percent on Monday, a second straight day, ending the day at $11.03 apiece following its impressive earnings performance in the first quarter, coupled with a highly optimistic outlook for the rest of the year.

In a statement, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it swung to a net income of $32,000 from a net loss of $35.38 million in the same period a year earlier as revenues jumped by 57 percent to $145.5 million from $92.76 million year-on-year, thanks to the strong performance of its hereditary angioedema treatment, Orladeyo.

Looking ahead, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it now expects to be fully profitable for the rest of the year ahead of its original target.

Revenues from Orladeyo alone were expected to settle between $580 million and $600 million, higher than the $535 million to $550 million targeted previously.

Full-year operating expenses were also targeted to settle only between $440 million and $450 million, from the previous $425 million to $435 million.